Home » OSCIENT PHARMACEUTICALS CORPORATION AGREES TO ACQUIRE CARDIOVASCULAR THERAPY ANTARA 130 MG (FENOFIBRATE) CAPSULES FROM RELIANT PHARMACEUTICALS, INC. FOR ABOUT $78 MILLION
OSCIENT PHARMACEUTICALS CORPORATION AGREES TO ACQUIRE CARDIOVASCULAR THERAPY ANTARA 130 MG (FENOFIBRATE) CAPSULES FROM RELIANT PHARMACEUTICALS, INC. FOR ABOUT $78 MILLION
Oscient Pharmaceuticals has agreed to acquire U.S. rights to the cardiovascular product ANTARA 130 mg (fenofibrate) capsules from Reliant Pharmaceuticals. ANTARA is part of the $1 billion fenofibrate market and will be commercialized by Oscient's national
sales force, which currently is marketing FACTIVE (gemifloxacin mesylate) tablets
and TESTIM® 1% testosterone gel, upon closing.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May